UTHR
United Therapeutics Corporation
485.50$
+2.1%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +13.8% | +9.1% | +7.9% | -5.7% | -11.0% | +2.4% | +13.6% | +14.9% | +20.2% | +23.6% | +10.6% | |
| – | -45.2% | +5.3% | +45.4% | +88.0% | -40.8% | -8.1% | +13.3% | +19.8% | +75.5% | +20.3% | +24.1% | |
| – | +20.1% | +9.3% | +6.1% | -11.8% | -6.9% | +3.3% | +13.7% | +14.5% | +15.7% | +24.0% | +9.0% | |
| – | +1.1% | -39.8% | +79.3% | +35.3% | +230.4% | -69.8% | +51.0% | -40.2% | +26.4% | +17.9% | +14.3% | |
| – | +19.7% | -35.2% | +14.5% | -22.2% | +33.3% | +33.9% | +9.1% | +3.4% | -5.0% | +37.2% | +12.9% | |
| – | +11.8% | -33.4% | +28.1% | +4.9% | +143.5% | -48.5% | +28.9% | -19.6% | +9.3% | +34.5% | +7.6% | |
| – | +29.7% | +51.9% | -23.2% | -1.2% | -123.3% | – | -6.4% | +76.2% | +20.9% | +16.2% | +10.2% | |
| – | -73.1% | -17.6% | +130.8% | +54.4% | +218.0% | -46.8% | -20.9% | +74.2% | +83.0% | -27.7% | -54.5% | |
| – | +98.9% | +1.5% | -27.4% | -1.4% | -121.7% | – | -7.0% | +60.1% | +34.1% | +20.8% | +11.4% | |
| – | +112.2% | -11.8% | +1.5% | -51.7% | -135.7% | – | -4.8% | +89.1% | +29.6% | +18.8% | +10.3% | |
| – | +91.6% | +9.5% | -41.4% | +41.0% | -117.7% | – | -7.6% | +52.9% | +35.4% | +21.4% | +11.7% | |
| – | +88.2% | +0.8% | -3.4% | -20.4% | -108.9% | – | +14.0% | +41.2% | +33.3% | +19.3% | +9.9% |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.